Healios K.K. (HLOSF) Stock Price, News & Analysis

Company Overview

Healios K.K. is a Japanese biotechnology company focused on developing regenerative medicine and cell therapies. Its research draws on induced pluripotent stem cell (iPSC) technology and somatic stem cell platforms, with the goal of treating serious diseases that have limited treatment options.

The company’s development programs have included HLCM051, a stem cell therapy investigated for conditions such as acute ischemic stroke and acute respiratory distress syndrome, as well as iPSC-based approaches for diseases including retinal disorders. These are investigational programs, not descriptions of commercially available treatments.

Founded in 2011 and headquartered in Tokyo, Healios has worked with academic and industry partners in Japan and internationally. The company was founded by Hardy Kagimoto, who has served as its chief executive.

Key Stats

• Today's Range: $1.80 to $1.80
• 50-Day Range: $1.80 to $1.80
• 52-Week Range: $1.80 to $4.45
• Volume: N/A
• Average Volume: 300 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Healios K.K. Stock Analysis - MarketRank™

Healios K.K. scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Healios K.K..

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Healios K.K. is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Healios K.K. is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Healios K.K. has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Healios K.K. has recently increased by 30.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Healios K.K. does not currently pay a dividend.

Dividend Growth

Healios K.K. does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Healios K.K. this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Healios K.K. insiders have not sold or bought any company stock.

Percentage Held by Institutions

20.34% of the stock of Healios K.K. is held by institutions.

Company Calendar

• Today: 11/09/2026
• Next Earnings (Estimated): 11/12/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HLOSF
• CIK: N/A
• Web: healios.co.jp
• Phone: 81357778308
• Fax: N/A
• Employees: 75
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A